Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
$7.55
-$0.14(-2.20%)
At close: 4:00 PM EST
$7.55
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$2.24 - $12.34
Previous CloseN/A
Volume165.32K
Average Volume (3M)1.01M
Market Cap
$434.80M
Enterprise Value$204.94M
Total Cash (Recent Filing)$305.06M
Total Debt (Recent Filing)$22.26M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Feb 27, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding57,135,075
10 Day Avg. Volume773,570
30 Day Avg. Volume1,005,223
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.59
Price to Sales (P/S)8120.72
P/FCF Ratio-2.17
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.71K
Enterprise Value/Gross Profit-2.12
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$33.83Price Target Upside348.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$19.01M
Bulls Say, Bears Say
Bulls Say
Clinical Durability And SafetyExtended follow-up demonstrates consistent visual acuity maintenance, retinal anatomic control, and no new treatment-related intraocular inflammation, supporting a favorable long-term safety and durability profile for 4D-150.
Enrollment And Commercial OpportunityEnrollment in the 4FRONT program has exceeded expectations with more than 200 patients randomized, indicating strong clinical interest and bolstering commercial upside for 4D-150 in retinal indications including DME.
Partnership And FinancingExclusive license with Otsuka provides an $85M upfront payment, expected cost sharing and potential milestone and royalty payments, strengthening cash resources and enabling progression of 4D-150 into pivotal DME development.
Bears Say
Off-target Expression Safety RiskHigher doses of 4D-710 produced transgene expression above target levels and in unintended cell types, raising concerns about off-target effects and safety at elevated doses.
Regulatory And Development RiskDose-dependent off-target findings could prompt additional safety studies or narrower dosing requirements, potentially complicating regulatory review and increasing development timelines or costs for 4D-710.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $12.34 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $434.80M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Feb 27, 2026 which is in 40 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.027.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -0.53.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 57,135,075 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went down -3.143%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (348.08% Upside)
$33.83 (348.08% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.32%
12-Months-Change
Fundamentals
Return on Equity
-45.38%
Trailing 12-Months
Asset Growth
-29.81%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$33.83
▲(348.08% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
2.20% Insiders
10.95% Mutual Funds
0.77% Other Institutional Investors
70.63% Public Companies and
Individual Investors